PAX-101 (IV Suramin) for ASD
PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting anti-purinergic therapy and has reported positive results from a dose range study. The results of our Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
PAX-101 (IV Suramin) for FXTAS
PAX-101 has been evaluated in several preclinical studies of Fragile X related animal models. PaxMedica intends to submit an Investigational New Drug (IND) application and start a Phase 2 study in 2021. PAX-101 for FXTAS is expected to qualify for Orphan Drug exclusivity.
PAX-102 (Intranasal Suramin)
PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
PaxMedica has conducted several preclinical studies to evaluate other anti-purinergic therapies (APTs) that are more selective to specific purinergic receptors and may offer additional benefits over suramin.